financetom
Business
financetom
/
Business
/
Wells Fargo's Medium-Term ROTCE Targets a "Good" Follow-up to Q2 Assets Cap Elimination, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wells Fargo's Medium-Term ROTCE Targets a "Good" Follow-up to Q2 Assets Cap Elimination, Oppenheimer Says
Oct 15, 2025 8:04 AM

10:41 AM EDT, 10/15/2025 (MT Newswires) -- Wells Fargo ( WFC ) raising its medium-term return on tangible common equity guidance to 17% to 18% during Q3 earnings call was a "good" follow-up to assets cap elimination in Q2, Oppenheimer said in a Wednesday research report.

Fiscal Q3 operating trends, including reported EPS of $1.66, were slightly better than expected, driven by core revenue of $21.40 billion, according to the note.

"Our 2026 estimate goes up by about 3% due to this quarter's favorable trends. There was nothing not to like about the quarter, but for the time being, we prefer Bank of America (BAC) and Citigroup (C) on better valuation," analysts wrote.

The brokerage said it had a perform rating on the stock.

Price: 86.98, Change: +2.42, Percent Change: +2.86

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
State Street's Q3 Earnings, Revenue Rise
State Street's Q3 Earnings, Revenue Rise
Oct 17, 2025
07:42 AM EDT, 10/17/2025 (MT Newswires) -- State Street (STT) reported Q3 earnings Friday of $2.78 per diluted share, up from $2.26 a year earlier. Analysts polled by FactSet expected $2.61. Revenue for the quarter ended Sept. 30 was $3.55 billion, up from $3.26 billion a year earlier. Analysts surveyed by FactSet expected $3.46 billion. ...
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
Oct 17, 2025
Oct 17 (Reuters) - Rani Therapeutics ( RANI ) said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical ( CHGCF ), with an option to extend it to up to five drugs, potentially bringing the total deal value to $1.09 billion. ...
XORTX Therapeutics Jumps 45% on US$3 Million Deal to Buy Renal Program From Vectus Biosystems
XORTX Therapeutics Jumps 45% on US$3 Million Deal to Buy Renal Program From Vectus Biosystems
Oct 17, 2025
07:44 AM EDT, 10/17/2025 (MT Newswires) -- XORTX Therapeutics ( XRTX ) which has surged 45% higher in New York trading, said Friday it is acquiring a renal anti-fibrotic therapeutic program from Vectus Biosystems, listed on the Australian Securities Exchange, for US$3 million in shares. The program, which includes a new chemical entity, VB4-P5, and its intellectual property, regulatory documentation,...
Huntington Bancshares' Q3 Earnings, Revenue Increase
Huntington Bancshares' Q3 Earnings, Revenue Increase
Oct 17, 2025
07:18 AM EDT, 10/17/2025 (MT Newswires) -- Huntington Bancshares ( HBAN ) reported Q3 earnings Friday of $0.41 per diluted share, up from $0.33 a year earlier. Analysts polled by FactSet expected $0.37. Revenue for the quarter ended Sept. 30 was $2.15 billion, compared with $1.89 billion a year earlier. Analysts polled by FactSet expected $2.05 billion. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved